Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Misoprostol Ripening Efficacy With Dilapan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women undergoing labor induction with a gestation of ≥37 weeks (based on a sure last menstrual period and an ultrasound done before 22 0/7 weeks)~2. Live fetus with in cephalic presentation~3. Singleton pregnancy~4. Able to provide informed consent for participation in the study~Exclusion Criteria:~1. Contraindication for vaginal delivery~2. Age less than 18 years~3. Prior uterine scar from a cesarean section or myomectomy~4. Patients who have HELLP syndrome or eclampsia~5. Active genital herpes at the time of labor induction~6. Complex medical problems that may require assistance with second stage of labor~7. Bishop score ≥ 6~8. Major fetal congenital anomalies (as assessed by investigator)~9. Premature rupture of membranes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dilapan group (Type: EXPERIMENTAL): Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed.
- Misoprostol group (Type: EXPERIMENTAL): Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).